Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLXN Silexion Therapeutics Corp

Post-Mkt 08-05 18:36:25 EDT

1.80

-0.10

-5.26%

盘后1.84

+0.04+2.27%

18:30 EDT

High1.95	Low1.73	Vol36.07K
Open1.95	D1 Closing1.90	Amplitude11.60%
Mkt Cap1.91M	Tradable Cap1.91M	Total Shares1.06M
T/O67.06K	T/O Rate3.41%	Tradable Shares1.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.8,"timestamp":1785960000000,"preClose":1.9,"halted":0,"volume":36065,"hourTrading":{"tag":"盘后","latestPrice":1.8409,"preClose":1.8,"latestTime":"18:30 EDT","volume":598,"amount":1032.9096726,"timestamp":1785969024910,"change":0.0409,"changeRate":0.022722,"amplitude":0.081389},"delay":0,"changeRate":-0.052631578947368356,"floatShares":1058700,"shares":1063117,"eps":-63.78105,"marketStatus":"Post-Mkt","change":-0.1,"latestTime":"08-05 18:36:25 EDT","open":1.95,"high":1.9504,"low":1.73,"amount":67063.8376485,"amplitude":0.116,"askPrice":1.86,"askSize":2,"bidPrice":1.6,"bidSize":120,"shortable":0,"etf":0,"ttmEps":-63.78105,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1785974400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.9,"preHourTrading":{"tag":"盘前","latestPrice":1.94,"preClose":1.9,"latestTime":"09:29 EDT","volume":514,"amount":971.5955418,"timestamp":1785936541104,"change":0.04,"changeRate":0.021053,"amplitude":0.036789},"postHourTrading":{"tag":"盘后","latestPrice":1.8409,"preClose":1.8,"latestTime":"18:30 EDT","volume":598,"amount":1032.9096726,"timestamp":1785969024910,"change":0.0409,"changeRate":0.022722,"amplitude":0.081389},"volumeRatio":0.095477},"requestUrl":"/m/hq/s/SLXN/tweets","defaultTab":"tweets","newsList":[{"id":"2656559067","title":"Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559067","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559067?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:16","pubTimestamp":1785849372,"startTime":"0","endTime":"0","summary":"Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancersSilexion Therapeutics reported new preclinical results for SIL204, extending earlier findings disclosed ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL3xJwvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4112","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SLXN","IE00BKPKM429.USD","SG9999014021.USD","BCDF","IE00BN0W2T93.GBP","BK4585","BK4588","NDAQ","SG9999014013.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559706","title":"Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559706?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849330,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4411EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656996183","title":"Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2656996183","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656996183?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:07","pubTimestamp":1785528442,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics director Amnon Peled resigns for personal reasonsProfessor Amnon Peled resigned from the board of Silexion Therapeutics for personal reasons, effective Aug. 1, 2026.The resignati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL11FsMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895299","title":"Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895299?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:30","pubTimestamp":1785331817,"startTime":"0","endTime":"0","summary":"WSW, NY, July 29th, 2026, FinanceWire Silexion Therapeutics (NASDAQ:SLXN) just announced that it initiated its Phase 2/3 clinical trial of SIL204 a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","HYLG","TQQQ","QLD","QQQE","TQQY","TECS","QYLG","MNQmain","BK4139","QID","SQQQ","NVIB","QQQ","QQQY","QQQJ","NQmain","NVIW.SI",".IXIC","QQQM","GPIQ","JEPQ","FTEC","PSQ","IDNA","QQQA","MEDX","IYW","ONEQ","GDOC","NDX","QDTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655864843","title":"Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2655864843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655864843?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861089","title":"Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861009","title":"Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861009?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653788904","title":"Silexion Therapeutics Shareholders Raise Authorized Share Capital Via Memorandum Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653788904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653788904?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:12","pubTimestamp":1784664775,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics shareholders raise authorized share capital via memorandum amendmentSilexion Therapeutics shareholders backed an amendment to its Cayman Islands memorandum, lifting authorized sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL3M2RXp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646178028","title":"Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646178028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646178028?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:50","pubTimestamp":1782319815,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silexion Therapeutics (SLXN) and Viking Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-silexion-therapeutics-slxn-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-silexion-therapeutics-slxn-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VKTX","BK4585","SLXN","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645649028","title":"Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2645649028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645649028?lang=en_us&edition=fundamental","pubTime":"2026-06-24 13:39","pubTimestamp":1782279551,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42V0WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836065","title":"Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836065?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218419,"startTime":"0","endTime":"0","summary":"Silexion won unconditional clearance from Germany’s BfArM to start its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.The authorization positions the company to launch the study in Germany alongside previously secured approval in Israel.First patient dosing is expected in the coming weeks, subject to site activation timelines.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL7RcXSq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SLXN","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4112","NDAQ","BK4588","BK4585","SG9999014005.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836053","title":"Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836053?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA6641FH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645360558","title":"Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645360558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645360558?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA6641FH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022179","title":"Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022179?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:38","pubTimestamp":1782131887,"startTime":"0","endTime":"0","summary":"Silexion outlined SIL204, an siRNA designed to silence KRAS gene expression with dual delivery targeting primary pancreatic tumors and micrometastases.Program focus is locally advanced pancreatic cancer; KRAS mutations cited in 92% of cases, with SIL204 targeting more than 74% of PDAC KRAS mutations.Total addressable market estimate for localized advanced pancreatic cancer: U.S. about USD 2 billion; E.U. about USD 3 billion.Phase 2/3 trial plan: safety run-in to start mid-2026 with completion expected in Q2 2027; Phase 2 expansion to start Q3 2027.Phase 3 confirmatory segment targeted to start Q3 2030; interim results flagged for 2028 with potential sample size adjustment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therape","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbrnMYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760946","title":"Silexion Therapeutics management to attend BIO International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760946","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760946?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:30","pubTimestamp":1781641857,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics management will attend the 2026 BIO International Convention in San Diego on June 22-25.One-on-one meetings with management are scheduled during the convention.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLrPyMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0314104364.USD","LU2210149790.SGD","BK4112","BK4139","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SLXN","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4588","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218270","title":"Silexion Therapeutics files to sell 859,609 ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218270?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:10","pubTimestamp":1781295049,"startTime":"0","endTime":"0","summary":"16:08 EDT Silexion Therapeutics (SLXN) files to sell 859,609 ordinary shares for holders Published first on TheFly – the ultimate source for real-t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-859609-ordinary-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-859609-ordinary-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621796","title":"Silexion Therapeutics executes 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621796","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:02","pubTimestamp":1780052564,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics set a 1-for-10 reverse share split, effective May 28, 2026, subject to board confirmation tied to Nasdaq bid-price compliance.Authorized share capital to be consolidated to US$796,500 divided into 5,900,000 ordinary shares with a par value of US$0.135.Issued ordinary shares to consolidate to 407,471 from 4,074,710, based on the April 7, 2026 share count.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL4LfKm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639124336","title":"Silexion Therapeutics Corp trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2639124336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639124336?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:50","pubTimestamp":1780012259,"startTime":"0","endTime":"0","summary":"19:50 EDT Silexion Therapeutics (SLXN) Corp trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514000","title":"Silexion Therapeutics announces 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514000","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514000?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798645,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics will execute a 1-for-10 reverse share split, effective after the May 28 market close.Shares start trading on a split-adjusted basis on Nasdaq at the May 29 open under ticker SLXN.Each 10 ordinary shares will convert into 1 share; par value rises to $0.135 from $0.0135.No fractional shares will be issued; DTC participants entitled to fractions will receive rounded-up whole shares.Move targets Nasdaq’s $1 minimum bid requirement, aiming to support listing compliance and future equity financing flexibility.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLGXXDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210149790.SGD","IE00BN0W2W23.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SLXN","BK4112","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU0314104364.USD","BK4139","IE00BKPKM429.USD","BK4585","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638702514","title":"Silexion Therapeutics Announces 1-for-10 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2638702514","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638702514?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA6VRR3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.2245},{"period":"1month","weight":-0.2817},{"period":"3month","weight":-0.6678},{"period":"6month","weight":-0.8742},{"period":"1year","weight":-0.979},{"period":"ytd","weight":-0.901}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.016335},{"month":2,"riseRate":0.6,"avgChangeRate":-0.095221},{"month":3,"riseRate":0.8,"avgChangeRate":-0.040641},{"month":4,"riseRate":0.6,"avgChangeRate":-0.119987},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.024382},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.109699},{"month":7,"riseRate":0.833333,"avgChangeRate":0.002605},{"month":8,"riseRate":0.5,"avgChangeRate":-0.229684},{"month":9,"riseRate":0.6,"avgChangeRate":-0.230878},{"month":10,"riseRate":0.4,"avgChangeRate":-0.091257},{"month":11,"riseRate":0.4,"avgChangeRate":-0.018649},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12005}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Silexion Therapeutics Corp,SLXN,Silexion Therapeutics Corp股票,Silexion Therapeutics Corp股票老虎,Silexion Therapeutics Corp股票老虎国际,Silexion Therapeutics Corp行情,Silexion Therapeutics Corp股票行情,Silexion Therapeutics Corp股价,Silexion Therapeutics Corp股市,Silexion Therapeutics Corp股票价格,Silexion Therapeutics Corp股票交易,Silexion Therapeutics Corp股票购买,Silexion Therapeutics Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}